A new survey assessing awareness of and attitudes about biosimilars among medical specialists and pharmacists in Ireland found that majority of such experts say that they are familiar or very familiar with the term “biosimilar,” but many general practitioners (GPs) were either unable to define or had never heard the term.
A new survey assessing awareness of and attitudes about biosimilars among medical specialists and pharmacists in Ireland found that a majority of such experts say that they are familiar or very familiar with the term “biosimilar,” but many general practitioners (GPs) were either unable to define or had never heard the term. Study authors Joan O’Callaghan, School of Pharmacy, University College, Cork, Ireland, and colleagues published the results of their survey online in the June 27, 2017 issue of Regulatory Toxicology and Pharmacology.
The study’s authors invited physicians to complete a questionnaire during April and May of 2016, and community pharmacists received a postal questionnaire in August of 2015. Responses were received from 268 GPs, 109 medical specialists, and 143 community pharmacists. The final analysis included responses from 102 medical specialists, 254 GPs, and 125 community pharmacists. Medical specialists included dermatologists, endocrinologists, gastroenterologists, hematologists, nephrologists, neurologists, oncologists, and rheumatologists.
Many medical specialists claimed to be very familiar, with a complete understanding (44%), or familiar, with a basic understanding (41%), of the term “biosimilar.” Although familiarity among medical specialists was high, the researchers found that this level of familiarity was not consistent across the 3 professions surveyed. GPs were the least familiar with the term, with 1 in 4 saying that they had never heard the term biosimilar—possibly because GPs are not directly involved in the prescribing of biological drugs. “However, GPs are certainly involved in the treatment of patients receiving biological medicines; therefore it is important that GPs are informed about biosimilars,” the authors note.
With 1 in 5 healthcare professionals who had previously heard the term “biosimilar” responding that they believed biosimilars to be the same thing as generic medications, the authors questioned the level of understanding of biosimilars among some healthcare professionals, and said that the survey exposed some misconceptions about fundamental regulatory principles concerning biological drugs and biosimilars that should be better communicated to Irish healthcare professionals.
The specialists indicated they had concerns about biosimilars that range from slight to extreme in relation to:
Most specialists surveyed (>95%) opposed pharmacist-led substitution of biological drugs, though some thought it could be appropriate if agreed to by the clinician in advance. In addition, specialists who prescribe biosimilars (n = 43) were more likely to do so on treatment initiation (67%) rather than in a switch from an originator medication to a biosimilar (28%).
The authors noted that, in Ireland, unlike other countries, there is currently no national guidance in relation to switching from an innovator drug to a biosimilar; if biosimilar uptake is to be encouraged in Ireland, further guidance about switching and how best to manage this practice may be needed. “Notably, 19% of medical specialists who currently prescribe biosimilars indicated that they would be likely to switch to a biosimilar when a patient's response to the reference medicine was inadequate,” the authors said. This response highlights the need to inform prescribers that biosimilars are equivalent treatments to their reference medicines, offering comparable patient outcomes.
Another challenge that the survey exposed is that only 14% of pharmacists stated that they were comfortable with substitution without prescriber agreement. As pharmacists are ultimately responsible for the implementation of substitution policies at the pharmacy level, the survey results suggest that pharmacists have reservations about assuming responsibility for substitution without prescriber agreement, which is a situation that must be addressed.
The study’s authors conclude that targeted communication to medical specialists via professional societies, published literature, and educational events could help to reduce the information gap about biosimilar medicines. The most appropriate communication channels for GPs and community pharmacists are not as clear, but communication with professional societies may facilitate the transfer of knowledge to these professionals.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More
February 29th 2024In its annual biosimilars report, Cardinal Health provided updates on how provider acceptance growth, evolving payer dynamics, and the growing pipeline for biosimilars will shape the biosimilar landscape over the next 5 years.
Biosimilar Substitution Within OCM Could Result in Lower Total Cost of Care
February 16th 2024Researchers found that the total cost of care per oncology episode was significantly lowered when biosimilar substitution was implemented in Medicare’s Oncology Care Model (OCM), suggesting that biosimilar uptake can serve as a critical tool to mitigate risk and improve financial performance for providers.